A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Exclusion Criteria

• •1. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms.
• •2. Previous or co-existing malignancies.
• •3. Has a history of non-infectious ILD/pneumonitis that required steroids, or has current ILD/pneumonitis;
• •4. Subjects with active hepatitis B or active hepatitis C;
• •5. Subjects who have received systemic anti-tumor treatments 4 weeks prior to the initiation of the study treatment.
• •6. Subjects who have been treated with TOP1 inhibitors, TROP-2 ADC or ADCs with TOP1 inhibitors as payload.
• •7. Has unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.